KDR and gastric cancer: Targeted cancer therapies which interrupt oncogenic molecular pathways driven by mutations, overexpression or translocation of specific genes, such as trastuzumab, an antibody against HER2 (also known as ERBB2) and the VEGFR-2 antibody ramucirumab, have been successfully employed in gastric cancer treatment [29].